The North America Leukemia Therapeutics Market would witness market growth of 5.4% CAGR during the forecast period (2023-2029).
Leukemia is a specific type of blood cancer that is characterized by abnormal leukocyte cell proliferation. Either acute or chronic leukemia is the classification. When the DNA in blood cells termed leukocytes mutates or changes, it impairs the cells' capacity to regulate growth and division. Sometimes, these immune system-evading mutant cells proliferate unchecked and crowd out healthy blood cells. Adults over 55 are most likely to experience it.
Bleeding, bone pain, brushing, exhaustion, and fever are just a few of the symptoms that arise from a lack of healthy blood cells. Additionally, the treatment may combine targeted therapy, chemotherapy, and immunotherapy, depending on the needs of the patient. The need for better treatments that can enhance patient outcomes is growing as leukemia continues to be a major health concern.
Tyrosine kinase inhibitors (TKIs), which focus on particular genes or proteins implicated in leukemia cell proliferation and spread, have been developed as a result of this. More people are becoming aware of leukemia and the need for effective therapies, which has increased demand for leukemia medications including chemotherapy and targeted therapy pharmaceuticals. The regional increase in healthcare spending is also a major factor in the market's expansion. Targeted therapies are becoming more and more in demand as a result of the increased emphasis on customized care and the development of new diagnostic techniques.
Approximately 1 million new cancer cases were reported in the United States in 2019, and 599,589 people died from the disease, according to data released by the Centers for Disease Control and Prevention (CDC). For every 100,000 persons in the country, 439 new cancer cases were reported, 146 of whom died. According to the Canadian Government's Cancer Statistics, 43% of Canadian women and 45% of Canadian men will develop cancer during their lifetime. There will be an increase in the number of new cancer patients as Canada's population ages and grows. Many deaths in Canada are primarily caused by cancer. As a result, there will be significant investment prospects for the major market players in the regional market as the number of cancer patients rises.
The US market dominated the North America Leukemia Therapeutics Market by Country in 2022, and would continue to be a dominant market till 2029; thereby, achieving a market value of $3,338.3 million by 2029. The Canada market is poised to grow at a CAGR of 7.8% during (2023 - 2029). Additionally, The Mexico market would witness a CAGR of 6.8% during (2023 - 2029).
Based on Drug Class, the market is segmented into Targeted Therapy & Immunotherapy and Chemotherapy. Based on Distribution Channel, the market is segmented into Hospital Pharmacies, Drug Store & Retail Pharmacies and Online Providers. Based on Type, the market is segmented into Chronic Lymphocytic Leukemia, Acute Lymphocytic Leukemia, Chronic Myeloid Leukemia, Acute Myeloid Leukemia and Others. Based on countries, the market is segmented into U.S., Mexico, Canada, and Rest of North America.
Free Valuable Insights: The Worldwide Leukemia Therapeutics Market is Projected to reach USD 11.7 Billion by 2029, at a CAGR of 6%
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Gilead Sciences, Inc., Bristol Myers Squibb Company, Sanofi S.A., AbbVie, Inc., Teva Pharmaceuticals Industries Ltd., Lupin Limited, Amgen, Inc., Takeda Pharmaceutical Company Limited, Pfizer, Inc. and Novartis AG.
Scope of the Study
Market Segments Covered in the Report:
By Drug Class
- Targeted Therapy & Immunotherapy
- Chemotherapy
By Distribution Channel
- Hospital Pharmacies
- Drug Store & Retail Pharmacies
- Online Providers
By Type
- Chronic Lymphocytic Leukemia
- Acute Lymphocytic Leukemia
- Chronic Myeloid Leukemia
- Acute Myeloid Leukemia
- Others
By Country
- US
- Canada
- Mexico
- Rest of North America
Key Market Players
List of Companies Profiled in the Report:
- Gilead Sciences, Inc.
- Bristol Myers Squibb Company
- Sanofi S.A.
- AbbVie, Inc.
- Teva Pharmaceuticals Industries Ltd.
- Lupin Limited
- Amgen, Inc.
- Takeda Pharmaceutical Company Limited
- Pfizer, Inc.
- Novartis AG
Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 North America Leukemia Therapeutics Market, by Drug Class
1.4.2 North America Leukemia Therapeutics Market, by Distribution Channel
1.4.3 North America Leukemia Therapeutics Market, by Type
1.4.4 North America Leukemia Therapeutics Market, by Country
1.5 Methodology for the research
Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.1.1 Market Composition & Scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
Chapter 3. Competition Analysis - Global
3.1 KBV Cardinal Matrix
3.2 Recent Industry Wide Strategic Developments
3.2.1 Partnerships, Collaborations and Agreements
3.2.2 Product Launches and Product Expansions
3.2.3 Acquisition and Mergers
3.2.4 Approvals & Trails
3.3 Top Winning Strategies
3.3.1 Key Leading Strategies: Percentage Distribution (2019-2023)
3.3.2 Key Strategic Move: (Partnerships, Collaborations & Agreements: 2019, May – 2022, Dec) Leading Players
Chapter 4. North America Leukemia Therapeutics Market by Drug Class
4.1 North America Targeted Therapy & Immunotherapy Market by Country
4.2 North America Chemotherapy Market by Country
Chapter 5. North America Leukemia Therapeutics Market by Distribution Channel
5.1 North America Hospital Pharmacies Market by Country
5.2 North America Drug Store & Retail Pharmacies Market by Country
5.3 North America Online Providers Market by Country
Chapter 6. North America Leukemia Therapeutics Market by Type
6.1 North America Chronic Lymphocytic Leukemia Market by Country
6.2 North America Acute Lymphocytic Leukemia Market by Country
6.3 North America Chronic Myeloid Leukemia Market by Country
6.4 North America Acute Myeloid Leukemia Market by Country
6.5 North America Others Market by Country
Chapter 7. North America Leukemia Therapeutics Market by Country
7.1 US Leukemia Therapeutics Market
7.1.1 US Leukemia Therapeutics Market by Drug Class
7.1.2 US Leukemia Therapeutics Market by Distribution Channel
7.1.3 US Leukemia Therapeutics Market by Type
7.2 Canada Leukemia Therapeutics Market
7.2.1 Canada Leukemia Therapeutics Market by Drug Class
7.2.2 Canada Leukemia Therapeutics Market by Distribution Channel
7.2.3 Canada Leukemia Therapeutics Market by Type
7.3 Mexico Leukemia Therapeutics Market
7.3.1 Mexico Leukemia Therapeutics Market by Drug Class
7.3.2 Mexico Leukemia Therapeutics Market by Distribution Channel
7.3.3 Mexico Leukemia Therapeutics Market by Type
7.4 Rest of North America Leukemia Therapeutics Market
7.4.1 Rest of North America Leukemia Therapeutics Market by Drug Class
7.4.2 Rest of North America Leukemia Therapeutics Market by Distribution Channel
7.4.3 Rest of North America Leukemia Therapeutics Market by Type
Chapter 8. Company Profiles
8.1 Gilead Sciences, Inc.
8.1.1 Company overview
8.1.2 Financial Analysis
8.1.3 Research & Development Expenses
8.1.4 Recent strategies and developments:
8.1.4.1 Partnerships, Collaborations, and Agreements:
8.1.4.2 Acquisition and Mergers:
8.2 Bristol Myers Squibb Company
8.2.1 Company Overview
8.2.2 Financial Analysis
8.2.3 Regional Analysis
8.2.4 Research & Development Expenses
8.2.5 Recent strategies and developments:
8.2.5.1 Acquisition and Mergers:
8.2.5.2 Partnerships, Collaborations and Agreements:
8.2.5.3 Approvals and Trials:
8.3 Sanofi S.A.
8.3.1 Company Overview
8.3.2 Financial Analysis
8.3.3 Segmental and Regional Analysis
8.3.4 Research & Development Expense
8.3.5 Recent strategies and developments:
8.3.5.1 Partnerships, Collaborations, and Agreements:
8.3.5.2 Trials and Approvals:
8.3.5.3 Acquisitions and Mergers:
8.4 AbbVie, Inc.
8.4.1 Company Overview
8.4.2 Financial Analysis
8.4.3 Regional Analysis
8.4.4 Research & Development Expense
8.4.5 Recent strategies and developments:
8.4.5.1 Acquisition and Mergers:
8.4.5.2 Approvals & Trials:
8.5 Teva Pharmaceutical Industries Ltd.
8.5.1 Company Overview
8.5.2 Financial Analysis
8.5.3 Regional Analysis
8.5.4 Research & Development Expenses
8.5.5 Recent strategies and developments:
8.5.5.1 Product Launches and Product Expansions:
8.6 Lupin Limited
8.6.1 Company Overview
8.6.2 Financial Analysis
8.6.3 Recent strategies and developments:
8.6.3.1 Product Launches and Product Expansions:
8.7 Amgen, Inc.
8.7.1 Company Overview
8.7.2 Financial Analysis
8.7.3 Regional Analysis
8.7.4 Research & Development Expenses
8.7.5 Recent strategies and developments:
8.7.5.1 Trials and Approvals:
8.8 Takeda Pharmaceutical Company Limited
8.8.1 Company Overview
8.8.2 Financial Analysis
8.8.3 Regional Analysis
8.8.4 Research & Development Expense
8.8.5 Recent strategies and developments:
8.8.5.1 Approvals & Trials:
8.9 Pfizer, Inc.
8.9.1 Company Overview
8.9.2 Financial Analysis
8.9.3 Regional & Segmental Analysis
8.9.4 Research & Development Expense
8.9.5 Recent strategies and developments:
8.9.5.1 Approvals & Trials:
8.9.5.2 Acquisition and Mergers:
8.10. Novartis AG
8.10.1 Company Overview
8.10.2 Financial Analysis
8.10.3 Research & Development Expense
8.10.4 Recent strategies and developments:
8.10.4.1 Partnerships, Collaborations, and Agreements:
8.10.4.2 Approvals & Trials:
TABLE 1 North America Leukemia Therapeutics Market, 2019 - 2022, USD Million
TABLE 2 North America Leukemia Therapeutics Market, 2023 - 2029, USD Million
TABLE 3 Partnerships, Collaborations and Agreements– Leukemia Therapeutics Market
TABLE 4 Product Launches And Product Expansions– Leukemia Therapeutics Market
TABLE 5 Acquisition and Mergers– Leukemia Therapeutics Market
TABLE 6 Approvals & Trials– Leukemia Therapeutics Market
TABLE 7 North America Leukemia Therapeutics Market by Drug Class, 2019 - 2022, USD Million
TABLE 8 North America Leukemia Therapeutics Market by Drug Class, 2023 - 2029, USD Million
TABLE 9 North America Targeted Therapy & Immunotherapy Market by Country, 2019 - 2022, USD Million
TABLE 10 North America Targeted Therapy & Immunotherapy Market by Country, 2023 - 2029, USD Million
TABLE 11 North America Chemotherapy Market by Country, 2019 - 2022, USD Million
TABLE 12 North America Chemotherapy Market by Country, 2023 - 2029, USD Million
TABLE 13 North America Leukemia Therapeutics Market by Distribution Channel, 2019 - 2022, USD Million
TABLE 14 North America Leukemia Therapeutics Market by Distribution Channel, 2023 - 2029, USD Million
TABLE 15 North America Hospital Pharmacies Market by Country, 2019 - 2022, USD Million
TABLE 16 North America Hospital Pharmacies Market by Country, 2023 - 2029, USD Million
TABLE 17 North America Drug Store & Retail Pharmacies Market by Country, 2019 - 2022, USD Million
TABLE 18 North America Drug Store & Retail Pharmacies Market by Country, 2023 - 2029, USD Million
TABLE 19 North America Online Providers Market by Country, 2019 - 2022, USD Million
TABLE 20 North America Online Providers Market by Country, 2023 - 2029, USD Million
TABLE 21 North America Leukemia Therapeutics Market by Type, 2019 - 2022, USD Million
TABLE 22 North America Leukemia Therapeutics Market by Type, 2023 - 2029, USD Million
TABLE 23 North America Chronic Lymphocytic Leukemia Market by Country, 2019 - 2022, USD Million
TABLE 24 North America Chronic Lymphocytic Leukemia Market by Country, 2023 - 2029, USD Million
TABLE 25 North America Acute Lymphocytic Leukemia Market by Country, 2019 - 2022, USD Million
TABLE 26 North America Acute Lymphocytic Leukemia Market by Country, 2023 - 2029, USD Million
TABLE 27 North America Chronic Myeloid Leukemia Market by Country, 2019 - 2022, USD Million
TABLE 28 North America Chronic Myeloid Leukemia Market by Country, 2023 - 2029, USD Million
TABLE 29 North America Acute Myeloid Leukemia Market by Country, 2019 - 2022, USD Million
TABLE 30 North America Acute Myeloid Leukemia Market by Country, 2023 - 2029, USD Million
TABLE 31 North America Others Market by Country, 2019 - 2022, USD Million
TABLE 32 North America Others Market by Country, 2023 - 2029, USD Million
TABLE 33 North America Leukemia Therapeutics Market by Country, 2019 - 2022, USD Million
TABLE 34 North America Leukemia Therapeutics Market by Country, 2023 - 2029, USD Million
TABLE 35 US Leukemia Therapeutics Market, 2019 - 2022, USD Million
TABLE 36 US Leukemia Therapeutics Market, 2023 - 2029, USD Million
TABLE 37 US Leukemia Therapeutics Market by Drug Class, 2019 - 2022, USD Million
TABLE 38 US Leukemia Therapeutics Market by Drug Class, 2023 - 2029, USD Million
TABLE 39 US Leukemia Therapeutics Market by Distribution Channel, 2019 - 2022, USD Million
TABLE 40 US Leukemia Therapeutics Market by Distribution Channel, 2023 - 2029, USD Million
TABLE 41 US Leukemia Therapeutics Market by Type, 2019 - 2022, USD Million
TABLE 42 US Leukemia Therapeutics Market by Type, 2023 - 2029, USD Million
TABLE 43 Canada Leukemia Therapeutics Market, 2019 - 2022, USD Million
TABLE 44 Canada Leukemia Therapeutics Market, 2023 - 2029, USD Million
TABLE 45 Canada Leukemia Therapeutics Market by Drug Class, 2019 - 2022, USD Million
TABLE 46 Canada Leukemia Therapeutics Market by Drug Class, 2023 - 2029, USD Million
TABLE 47 Canada Leukemia Therapeutics Market by Distribution Channel, 2019 - 2022, USD Million
TABLE 48 Canada Leukemia Therapeutics Market by Distribution Channel, 2023 - 2029, USD Million
TABLE 49 Canada Leukemia Therapeutics Market by Type, 2019 - 2022, USD Million
TABLE 50 Canada Leukemia Therapeutics Market by Type, 2023 - 2029, USD Million
TABLE 51 Mexico Leukemia Therapeutics Market, 2019 - 2022, USD Million
TABLE 52 Mexico Leukemia Therapeutics Market, 2023 - 2029, USD Million
TABLE 53 Mexico Leukemia Therapeutics Market by Drug Class, 2019 - 2022, USD Million
TABLE 54 Mexico Leukemia Therapeutics Market by Drug Class, 2023 - 2029, USD Million
TABLE 55 Mexico Leukemia Therapeutics Market by Distribution Channel, 2019 - 2022, USD Million
TABLE 56 Mexico Leukemia Therapeutics Market by Distribution Channel, 2023 - 2029, USD Million
TABLE 57 Mexico Leukemia Therapeutics Market by Type, 2019 - 2022, USD Million
TABLE 58 Mexico Leukemia Therapeutics Market by Type, 2023 - 2029, USD Million
TABLE 59 Rest of North America Leukemia Therapeutics Market, 2019 - 2022, USD Million
TABLE 60 Rest of North America Leukemia Therapeutics Market, 2023 - 2029, USD Million
TABLE 61 Rest of North America Leukemia Therapeutics Market by Drug Class, 2019 - 2022, USD Million
TABLE 62 Rest of North America Leukemia Therapeutics Market by Drug Class, 2023 - 2029, USD Million
TABLE 63 Rest of North America Leukemia Therapeutics Market by Distribution Channel, 2019 - 2022, USD Million
TABLE 64 Rest of North America Leukemia Therapeutics Market by Distribution Channel, 2023 - 2029, USD Million
TABLE 65 Rest of North America Leukemia Therapeutics Market by Type, 2019 - 2022, USD Million
TABLE 66 Rest of North America Leukemia Therapeutics Market by Type, 2023 - 2029, USD Million
TABLE 67 Key Information – Gilead Sciences, Inc.
TABLE 68 Key Information – Bristol Myers Squibb Company
TABLE 69 Key Information – Sanofi S.A.
TABLE 70 Key information – AbbVie, Inc.
TABLE 71 Key Information – Teva Pharmaceuticals Industries Ltd.
TABLE 72 Key Information – Lupin Limited
TABLE 73 Key Information – Amgen, Inc.
TABLE 74 Key Information – Takeda Pharmaceutical Company Limited
TABLE 75 Key Information – Pfizer, Inc.
TABLE 76 Key Information – Novartis AG
List of Figures
FIG 1 Methodology for the research
FIG 2 KBV Cardinal Matrix
FIG 3 Key Leading Strategies: Percentage Distribution (2019-2023)
FIG 4 Key Strategic Move: (Partnerships, Collaborations & Agreements: 2019, May – 2022, Dec) Leading Players
FIG 5 North America Leukemia Therapeutics Market Share by Drug Class, 2022
FIG 6 North America Leukemia Therapeutics Market Share by Drug Class, 2029
FIG 7 North America Leukemia Therapeutics Market by Drug Class, 2019 - 2029, USD Million
FIG 8 North America Leukemia Therapeutics Market Share by Distribution Channel, 2022
FIG 9 North America Leukemia Therapeutics Market Share by Distribution Channel, 2029
FIG 10 North America Leukemia Therapeutics Market by Distribution Channel, 2019 - 2029, USD Million
FIG 11 North America Leukemia Therapeutics Market Share by Type, 2022
FIG 12 North America Leukemia Therapeutics Market Share by Type, 2029
FIG 13 North America Leukemia Therapeutics Market by Type, 2019 - 2029, USD Million
FIG 14 North America Leukemia Therapeutics Market Share by Country, 2022
FIG 15 North America Leukemia Therapeutics Market Share by Country, 2029
FIG 16 North America Leukemia Therapeutics Market by Country, 2019 - 2029, USD Million
FIG 17 Recent strategies and developments: Gilead Sciences, Inc.
FIG 18 Recent strategies and developments: Bristol Myers Squibb Company
FIG 19 Recent strategies and developments: Sanofi S.A.